DEC 30, 2016 1:47 PM PST

Male Contraception Candidate Drug may Also Shrink Testicular Tumor

WRITTEN BY: Xuan Pham

An experimental drug that was originally intended to work for male contraception may also work to shrink testicular cancer.

The drug is a small-molecule inhibitor by the name of JQ1. Instead of working to influence changes at the DNA level, JQ1 affects changes at the epigenetic level. In particular, this drug interferes with protein binding at the bromodomain - a stretch of amino acids that “reads” certain chemical tags on histones.

"JQ1 inhibits those proteins that read these histone marks and thus changes the gene activity in the cell," explained Hubert Schorle from the Institute for Pathology at the University of Bonn, and the study’s senior author.

Previously, researchers showed that JQ1 inhibited an essential part of sperm development. Treatment of this drug in mice led to smaller testes, sperm count and motility. As such, it was considered for the part of a male contraceptive drug.

In studying the mechanisms of JQ1’s actions, researcher at the University of Bonn realized that the molecule could also influence testicular cancer development. JQ1 appears to inhibit bromodomain and extraterminal (BET) proteins, which in testicular cancer, triggers cellular stress signals and cause the cell to die.

"In a testicular cancer mouse model, the tumors began to shrink after administering JQ1," said Sina Jostes, the study’s lead author. "In contrast, healthy skin cells seem to tolerate JQ1 very well." The team showed positive tumor shrinkage in both cell culture and live animal models.

Jostes and colleagues also tested the effects of JQ1 alongside another histone deacetylase inhibitor known as romidepsin. This drug has previously been tested and approved for testicular cancer. However, the team reported that the combination of JQ1 and romidepsin seemed to have the greatest effect, especially in cancer types that proved resistant to therapy.

"In our study, we treated mice with both JQ1 and romidepsin," said Daniel Nettersheim, the study’s co-author. "This way, we achieved a similar effect alike JQ1 or romidepsin treatment alone, but we could reduce the quantities of both substances. Such a combination therapy to treat testicular tumors may be much better tolerated. Chemotherapy-resistant patients could also benefit from this."

Both the anticancer effects and the contraceptive effects of JQ1 are under further investigation.

Additional source:  University of Bonn

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 06, 2021
Cancer
A New Biomarker to Personalize Breast Cancer Therapy
SEP 06, 2021
A New Biomarker to Personalize Breast Cancer Therapy
The American Cancer Society estimates that over 280,000 women in the United States will be diagnosed with breast cancer ...
SEP 06, 2021
Drug Discovery & Development
Antibiotics Increase Colon Cancer Risk by 17%
SEP 06, 2021
Antibiotics Increase Colon Cancer Risk by 17%
People who take antibiotics are at an increased risk of developing colon cancer within five to ten years. The research w ...
SEP 27, 2021
Cancer
Inflammation Promotes Pancreatic Cancer Progression
SEP 27, 2021
Inflammation Promotes Pancreatic Cancer Progression
Inflammation occurs when the immune response, including immune cells and mediators they produce, protect you from danger ...
OCT 25, 2021
Cancer
Could Pomegranates Play a Role in Cancer Prevention or Treatment?
OCT 25, 2021
Could Pomegranates Play a Role in Cancer Prevention or Treatment?
Pomegranate (Punica granatum L) is an ancient fruit grown primarily in western Asia and Mediterranean regions.  ...
DEC 30, 2021
Cancer
Integrative Oncology Prolongs Breast Cancer Survival
DEC 30, 2021
Integrative Oncology Prolongs Breast Cancer Survival
We often describe cancer according to where it originates, such as breast cancer, lung cancer, or pancreatic cancer.&nbs ...
JAN 06, 2022
Cancer
Breakthrough COVID Cases Cause Concern for Cancer Patients
JAN 06, 2022
Breakthrough COVID Cases Cause Concern for Cancer Patients
As we enter the third year of the COVID-19 pandemic, we continue to learn more about the respiratory virus leading to a ...
Loading Comments...